



23rd September 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18392.46	+0.54%	+5.55%
S&P 500	2177.18	+0.65%	+6.52%
Nasdaq	5339.52	+0.84%	+6.63%
Nikkei	16754.02	-0.32%	-11.70%
Stoxx 600	347.864	+1.58%	-4.91%
CAC 40	4509.82	+2.27%	-2.74%
Oil /Gold			
Crude WTI	46.17	+2.28%	+24.11%
Gold (once)	1339.53	+1.03%	+26.09%
Currencies/Rates			
EUR/USD	1.1241	+0.91%	+3.48%
EUR/CHF	1.0871	-0.10%	-0.03%
German 10 years	-0.159	+169.92%	-125.13%
French 10 years	0.142	-40.04%	-85.57%

Economic releases :

Date	
23rd-Sept	8h45 FR GDP (2Q 1.4%E y/y)
	9h30 DE Manufacturing PMI Sep. (53.1E)
	9h30 DE Composite PMI Sep. (53.6E)
	10h00 EUZ -Manuf PMI Sep. (51.5 E)
	10h00 EUZ Composite PMI Sep. (52.8E)
	15h45 US Manuf. PMI Sep. (52E)

Upcoming BG events :

Date	
30th-Sept	Thematic Breakfast with Vimpelcom
28th-Oct	IMERYS (Paris roadshow)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference
28th-Nov/ 29th-Nov	2nd Paris Consumer Conference

Recent reports :

Date	
15th-Sept	Remy Cointreau : It keeps getting better
14th-Sept	Automotive Innovation: the only way to stand out!
9th-Sept	ENGIE The twelve labours of Engie
7th-Sept	FRESENIUS : ¡Salud!
6th-Sept	WIRECARD Ready to reconnect with the fundamentals
24th-Aug	AMS Catching the ball when it bounces - all a question of timing

List of our Reco & Fair Value : Please click here to download



ESSILOR

BUY, Fair Value EUR130 (+10%)

Short preview of Essilor's US operations ahead of US field trip

Next week Essilor is hosting a field trip in Dallas (TX) and Providence (RI) to present its strategy for North America, which accounts for 48% of total sales. Growth potential for Essilor nevertheless remains significant as the group continues to expand in fast-growing segments (online, sunglasses) and channels (e.g.: independent ECP alliance groups). We should also gain a good overview of the group's best-in-class supply chain (Rx labs, distribution centers) that leverages the group's growth catalysts.

FRESENIUS SE

BUY-Top Picks, Fair Value EUR78 (+7%)

Fresenius KABI diluted but short-term outlook still strong

In an interview given to Manager Magazin, FRE's CEO, Stephan Sturm, said that synergies of more than EUR50m should not be ruled out following the integration of Quironsalud. Also, FRE launched a generic of Cubicin (IV Gx) earlier this week and we believe this could benefit from the short-term outlook for the recently diluted KABI division. This might well enable KABI to keep up with high margin levels (above 40%) despite an easing in the US drug shortage situation.

In brief...

CAMPARI, Refinancing with favourable conditions

Yesterday, Campari announced that it has prepaid all US Private Placement Notes, which amount to USD310m and bear an average coupon of 5.82%.

MONCLER, Eurazeo to sell 6% stake in Moncler

Yesterday evening, ECIP (Eurazeo) announced its intention to sell 15m Moncler shares, representing a 6% stake, through an accelerated book-building process. Based on yesterday's closing price, this placement would amount to EUR234m.

VEOLIA ENVIRONNEMENT, Caisse des Dépôts announces its intention to place up to 22.5m shares in Veolia

French state-owned bank Caisse des Dépôts (CDC) announced yesterday evening that it was selling about 22.5 million shares in the French environmental services company Veolia through an accelerated book building process.

Luxury & Consumer Goods

Essilor

Price EUR118.45

Short preview of Essilor's US operations ahead of US field trip

Fair Value EUR130 (+10%)

BUY

Bloomberg	EF FP
Reuters	ESSI.PA
12-month High / Low (EUR)	123.6 / 103.0
Market Cap (EUR)	25,833
Ev (BG Estimates) (EUR)	27,503
Avg. 6m daily volume (000)	450.9
3y EPS CAGR	10.1%

	1 M	3 M	6 M	31/12/15
Absolute perf.	5.6%	1.3%	10.2%	3.0%
Consumer Gds	0.7%	2.6%	4.2%	-0.6%
DJ Stoxx 600	2.2%	1.9%	2.2%	-4.9%

YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	6,716	7,132	7,625	8,157
% change		6.2%	6.9%	7.0%
EBITDA	1,263	1,341	1,449	1,566
EBIT	1,183	1,271	1,379	1,501
% change		7.5%	8.5%	8.9%
Net income	757.1	846.6	923.3	1,017
% change		11.8%	9.1%	10.1%

	2015	2016e	2017e	2018e
Operating margin	17.6	17.8	18.1	18.4
Net margin	11.3	11.9	12.1	12.5
ROE	13.3	13.2	12.9	13.4
ROCE	20.0	20.1	20.9	21.5
Gearing	34.7	24.5	15.9	13.7


(€)	2015	2016e	2017e	2018e
EPS	3.57	3.96	4.32	4.76
% change	-	11.0%	9.1%	10.1%
P/E	33.2x	29.8x	27.2x	24.7x
FCF yield (%)	3.4%	3.6%	3.9%	4.1%
Dividends (€)	1.15	1.30	1.15	1.15
Div yield (%)	1.0%	1.1%	2.7%	3.5%
EV/Sales	4.2x	3.9x	3.5x	3.3x
EV/EBITDA	22.1x	20.5x	18.7x	17.2x
EV/EBIT	23.6x	21.6x	19.6x	17.9x

Next week Essilor is hosting a field trip in Dallas (TX) and Providence (RI) to present its strategy for North America, which accounts for 48% of total sales. Growth potential for Essilor nevertheless remains significant as the group continues to expand in fast-growing segments (online, sunglasses) and channels (e.g.: independent ECP alliance groups). We should also gain a good overview of the group's best-in-class supply chain (Rx labs, distribution centers) that leverages the group's growth catalysts.

ANALYSIS

- The US remains the world's largest optical market. At end-March 2016, the US vision care market was worth around USD40bn (or ~EUR36bn), representing approx. 40% of the global market. Growth in the US eyewear market was quite robust at 4.7% (12m ending March 2016) and interestingly, Rx lenses was the best-performing segment (+6.5%). We assume this outperformance vs. sunglasses (+5.5%) continued in Q2 since the latter was impacted by unfavourable weather conditions across the country.

US total Vision Care market (annual sales at end-March 2016, in USDbn):




Source: The Vision Council


- North America represents 44% of Lenses & Optical Instruments revenue. Except for an unusually soft Q2 (+1.5% LFL) marked by temporary issue at Transitions, the US market was a key catalyst for Essilor (+5% in 2014 and +4.4% in 2015) thanks to robust underlying trends as well as a successful combination of media campaigns (*Crizal*, *Varilux*, *Xperio*) and innovation. With its multi-channel/multi-segment approach, Essilor makes sure that it is always present in the most dynamic channels, such as the independent ECP alliances or buying groups.

- Essilor is consolidating the fast-growing ECP alliance channel. Last year the group acquired the largest member alliance in the US, *Vision Source* (4,071 doctors) and *PERC/IVA* (respectively 3,141 and 912 doctors), followed by *Opti-Port* (33 members, 400+ offices) in April. Consequently, Essilor now covers over 8,000 doctors, or >30% of the total channel (~25,000 independent eye doctors), which represent a significant growth opportunity for Essilor to push its products and services further. As highlighted by the two charts below, the independent ECP channel has constantly gained market share in the frame and lens segments thanks to a high level of expertise and service. *Vision Source* enjoyed particularly strong momentum with retail sales up ~13.5% in 2015 to USD2.5bn, as the second-largest optical retailer in the US according to *Vision Monday*, just behind *Luxottica*.

US frame market by channel (in USD):



US lens market by channel (in USD):




Source: The Vision Council

- Sunglass & Readers division: US sunglass market still underpenetrated. The right-hand chart on the next page shows that nearly 74% of sunglasses sold in the US retail for less than USD30, vs. an average retail price of EUR80 in Europe. Essilor favours premiumisation in the US sunglass market by: (i) increasing the sun lens standard (higher quality, more innovation), (ii) educating customers through media campaigns and (iii) developing its proprietary brands (*Foster Grant*, *Costa*, etc.), especially in more selective channels (independent opticians, etc.). The value segment is addressed by *FGX* sun brands (readers) that continues to penetrate new




channels and gain new accounts. Despite unfavourable weather conditions and poor trends within the performance segment, **Costa** (retail price: >USD150) remained in positive territory thanks to a media push, distribution gains (doctor alliances, travel retail) and geographical expansion across the US.



Source: The Vision Council

- Online business: a small but fast-growing channel.** We believe that Essilor's exposure to the US online business is slightly higher than the industry (online retail = ~5% of US total optical retail) and according to *The Vision Council*, the online channel had a 3.9% market share in the Rx frame segment, especially for entry-level products. As in other segments, Essilor has a multi-channel/multi-segment approach with three main BtoC online platforms: **(i) EyeBuyDirect** that sells value Rx eyeglasses and frames, **(ii) FramesDirect** mostly offers premium eyeglasses and sunglasses and **(iii) Coastal** that sells contact lenses and eyeglasses. Revenue from the first two websites grew in double digits in H1 while Coastal was lagging behind as the group is testing a new commercial proposal/customer experience. This online business will continue to be a key growth catalyst for Essilor, especially in the US.
- Supply chain: maintaining this best-in-class execution to capture growth potential.** During the field trip, we will visit the **Innovation & Technology Center** for North America (three in the world: Creteil, Dallas and Singapore) that focuses on product quality and consumer/market trends, as well as one of **Essilor's largest Rx labs** in the US (Omega Dallas), giving us a good overview of the group's key competitive advantages (R&D, customer-centric organisation, supply chain). Essilor has extensive coverage with 168 Rx labs, although the network has been streamlined in recent years (2010: 190 Rx labs). In our view, this is a consequence of the increasing importance of the seven export labs, two of them based in Mexico, to address the North American customers.



Source: Company Data

VALUATION

- Besides having a clearer view on Essilor's operations in North America, this event might be a good opportunity to have more colour on current trading after a soft Q2. Buy recommendation and FV of EUR130 confirmed.
- It is worth noting that presentations concerning the US market might also be of interest for Luxottica shareholders as a read-across, since the Italian group generates 56% of its revenue there.

NEXT CATALYSTS

- US field trip on 27-30th September // Q3 results on 21st October.

[Click here to download](#)



Analyst:
 Cedric Rossi
 33(0) 1 70 36 57 25
 crossi@bryangarnier.com

Analyst Consumer Team:
 Nikolaas Faes
 Loic Morvan
 Antoine Parison
 Virginie Roumage

Healthcare

Fresenius SE

Price EUR72.87

Fresenius KABI diluted but short-term outlook still strong

Fair Value EUR78 (+7%)

BUY-Top Picks

Bloomberg	FRE GR
Reuters	FREG.DE
12-month High / Low (EUR)	72.9 / 53.1
Market Cap (EUR)	39,813
Ev (BG Estimates) (EUR)	55,062
Avg. 6m daily volume (000)	1 033
3y EPS CAGR	12.6%

In an interview given to Manager Magazin, FRE's CEO, Stephan Sturm, said that synergies of more than EUR50m should not be ruled out following the integration of Quironsalud. Also, FRE launched a generic of Cubicin (IV Gx) earlier this week and we believe this could benefit from the short-term outlook for the recently diluted KABI division. This might well enable KABI to keep up with high margin levels (above 40%) despite an easing in the US drug shortage situation.

ANALYSIS


- Following the acquisition of Quironsalud by Fresenius SE, we are reiterating our BUY recommendation and raising our Fair Value to EUR78. As a reminder, we were pleased to see Fresenius' management reinforcing its hospital business (HELIOS), thereby bringing stability and visibility to both sales and earnings at a time when visibility at KABI (mainly a US IV generic business) could be decreasing slightly due to an easing in the drug shortage situation in the US.
- Regarding synergies that could be achieved from the integration of Quironsalud i.e. EUR50m announced, we stressed in our note (please see [here](#)) that they could be topped. In an interview given yesterday to Manager Magazin, CEO Stephan Sturm pointed out that this amount should be viewed as a minimum threshold. In the same interview, the CEO mentioned that other M&A deals are still on the agenda. Note that with a net debt/EBITDA ratio that we expected to be back at around 2.5x by mid-2017, bolt-on deals should not be ruled out (KABI's turn?).
- Regarding decreasing visibility at KABI, note that this is due to an easing of the drug shortage situation in the US, which impacted NA growth rate during the second quarter (-6%CC), but has to be nuanced, at least in the short term. Indeed, we highlighted management's ability to 1/ target key drugs (cf chart below) enabling KABI to 2/ increase its EBIT margin in the region i.e. NA EBIT margin +210bp in Q2 to 43.1% of sales. The latter point remains the most important in our view.

	1 M	3 M	6 M	31/12/15
Absolute perf.	9.9%	11.2%	17.6%	10.5%
Healthcare	0.8%	2.7%	6.8%	-6.4%
DJ Stoxx 600	2.2%	1.9%	2.2%	-4.9%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	27,626	28,927	33,694	36,132
% change		4.7%	16.5%	7.2%
EBITDA	4,990	5,407	6,213	6,756
EBIT	3,875	4,250	4,865	5,311
% change		9.7%	14.5%	9.2%
Net income	1,358	1,623	1,864	2,064
% change		19.5%	14.9%	10.7%

	2015	2016e	2017e	2018e
Operating margin	14.0	14.7	14.4	14.7
Net margin	4.9	5.6	5.5	5.7
ROE	7.2	7.9	8.3	8.4
ROCE	3.8	4.3	4.8	5.1
Gearing	118.4	107.2	101.0	91.6

(EUR)	2015	2016e	2017e	2018e
EPS	2.62	2.97	3.38	3.74
% change	-	13.6%	13.6%	10.7%
P/E	27.9x	24.5x	21.6x	19.5x
FCF yield (%)	1.8%	4.0%	1.8%	4.3%
Dividends (EUR)	1.69	1.93	2.21	2.45
Div yield (%)	2.3%	2.6%	3.0%	3.4%
EV/Sales	1.9x	1.9x	1.8x	1.7x
EV/EBITDA	10.7x	10.2x	9.8x	9.1x
EV/EBIT	13.8x	13.0x	12.6x	11.6x



- Earlier this week, KABI announced the launch of another IV drug in the US: Daptomycin, an antibiotic indicated in the treatment of serious/complicated blood, skin or bone joint infections. This is the fourth IV drug launch in the US this year (guidance of 6-10 drug launches). As such, we reiterate our view that launch guidance should not be at risk as launches are expected to be back-end loaded towards the end of the year.

While most of the IV drugs launched in the US by KABI rarely drive more than EUR100m in sales, daptomycin holds greater potential in our view. The drug is marketed under the trade name Cubicin by Merck & Co, following its acquisition of Cubist for USD9.5bn in 2014. US sales of Cubicin amounted to approx. USD1bn in 2015. Now that Cubicin has lost its patent protection in the US (June 2016), TEVA and KABI entered the market on 15th and 20th September respectively. We have identified several other Gx drugmakers that could have an interest in entering this market as they have filed ANDAs (namely Crane, Sagent, Stride, Agila, Hospira, Dr. Reddy and Actavis), KABI and TEVA however should benefit from being the first movers and enjoy a larger market share in coming months. This market share will depend on Merck & Co's defence strategy concerning whether or not it will align with the generic price (~30% discount). Given Merck & Co's statement that it should "lose a significant market share", it is fair to assume that sales are set to decrease by 50-60% in 2017e, due to KABI and TEVA as well as other generic companies, albeit to a lesser extent. Note that GSK's augmentin lost 50% of its sales one year after the introduction of Gx and a further 25% during the second year.



In all, we believe that KABI should derive EUR10-15m and EUR100-125m in sales from daptomycin in Q4 2016 and 2017 respectively (BGe), which should 1/ make the product one of the most important in KABI's portfolio i.e. close to 5% of KABI sales in 2017e and 2/ has the potential to contribute alone to 1/3rd of KABI's 2017e mid-single digit growth.

Once again, this bodes well for our view that FRE's management effectively targets key Gx, which in the short term should continue to benefit KABI margins. As a reminder, KABI's sales and EBIT guidances were raised following Q2 results, from low single digit and roughly flat growth to 3-5% growth for both figures.

VALUATION

- We reiterate our BUY recommendation and EUR78 Fair Value.
- Fresenius SE is in our Q3 Top-Picks list.

NEXT CATALYSTS

- 27th October: Q3 results

[Click here to download](#)



Analyst :
Hugo Solvet
33(0) 1 56 68 75 57
hsolvet@bryangarnier.com

Sector Team :
Mickael Chane Du
Eric Le Berrigaud

Food & Beverages

Campari

Price EUR10.04

Refinancing with favourable conditions

Fair Value EUR10,5 vs. EUR9,7 (+5%)

BUY

Bloomberg	CPR.IM
Reuters	CPR.MI
12-month High / Low (EUR)	10.0 / 6.9
Market Cap (EUR)	5,831
Avg. 6m daily volume (000)	1 234

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.3%	19.0%	15.4%	25.5%
Food & Bev.	1.2%	3.7%	5.3%	1.1%
DJ Stoxx 600	2.2%	1.9%	2.2%	-4.9%

	2015	2016e	2017e	2018e
P/E	31.2x	28.0x	21.5x	19.6x
Div yield (%)	0.9%	0.9%	1.0%	1.0%

ANALYSIS

- Yesterday, Campari announced that it has prepaid all US Private Placement Notes, which amount to USD310m and bear an average coupon of 5.82%. The operation was financed via a EUR300m loan maturing in three years and with a coupon of 0.75% over 3 months Euribor. In addition, bonds worth EUR350m are due to mature in October. Their average coupon stands at 5.375%. As a result, we estimate that the average cost of debt has dropped from 4.4% to 2.8%. Our EPS estimates are revised upwards by 4% on average over the next three years.

VALUATION

- Our Fair Value is adjusted to EUR10.5 as we factor 2.8% into our WACC.

NEXT CATALYST

- The group is to release its 9M results on 8th November.

[Click here to download](#)

Virginie Roumage, vroumage@bryangarnier.com

Luxury & Consumer Goods

Moncler

Price EUR15.67

Eurazeo to sell 6% stake in Moncler

Fair Value EUR17,5 (+12%)

BUY


Bloomberg	MONC.IM
Reuters	MONC.MI
12-month High / Low (EUR)	16.2 / 12.2
Market Cap (EURm)	3,920
Avg. 6m daily volume (000)	896.5

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.2%	2.9%	7.3%	21.3%
Pers & H/H Gds	-2.0%	-0.8%	2.3%	0.7%
DJ Stoxx 600	0.7%	0.7%	0.5%	-6.4%

	2015	2016e	2017e	2018e
P/E	22.9x	20.9x	18.9x	17.1x
Div yield (%)	0.9%	1.1%	1.3%	1.4%

ANALYSIS

- Yesterday evening, ECIP (Eurazeo) announced its intention to sell 15m Moncler shares, representing a 6% stake, through an accelerated book-building process. Based on yesterday's closing price, this placement would amount to EUR234m.
- After the accelerated book building process, Eurazeo's stake will be reduced to 9.5% from 15.5% prior to the operation while the Italian group's free float will increase to approx. 47%, as shown by the two graphs below. Note that Eurazeo currently has two members on the Board of Directors: 1/ Virginie Morgon (Vice Chairman of the BoD) and 2/ Vivianne Akriche (Director).



- *Source: Company Data, Bryan Garnier & Co.*
- As of 3rd August, the holding company belonging to Remo Ruffini welcomed two new strategic investors: 1/ Singapore's sovereign fund **Temasek** and 2/ Dufry Chairman **Juan Carlos Torres**, who have acquired 24.4% of Ruffini Partecipazioni (75.6% still owned by Mr Remo Ruffini) and bring interesting expertise for the future development of Moncler: 1/ **Temasek has a deep knowledge of the Asian region** that already accounts for 38% of sales and is a key growth driver for the group (+30% FX-n in H1), but still harbours promising growth opportunities; 2/ **Mr Juan Carlos Torres** is Executive Chairman of the leading travel retail group **Dufry** and will **naturally** help Moncler to increase its exposure to this fast-growing channel (five stores at the end of H1, only ~2% of sales vs. ~6% of the luxury industry).

VALUATION

- After gaining 21% ytd, the Moncler share is the best-performing stock in our luxury sample. However, the valuation remains attractive as the stock trades at 12x 2017e EV/EBIT, in line with our luxury average excl. Hermès at 11.8x.
- **Hence any weakness in the share price is a very interesting entry point in our view**, considering the promising growth prospects (sales CAGR 2015-18e of 10.6% vs. -4% for our luxury sample).

NEXT CATALYSTS

- Moncler is to release its Q3 2016 sales on 8th November.

[Click here to download](#)

Cédric Rossi, crossi@bryangarnier.com

Utilities

Veolia Environnement

Price EUR20.62

Caisse des Dépôts announces its intention to place up to 22.5m shares in Veolia

Fair Value EUR23,5 (+14%)

BUY-Top Picks

Bloomberg	VIE.FP
Reuters	VIE.PA
12-month High / Low (EUR)	22.9 / 18.1
Market Cap (EUR)	11,617
Avg. 6m daily volume (000)	1,778


	1 M	3 M	6 M	31/12/15
Absolute perf.	6.9%	2.5%	0.6%	-5.7%
Utilities	0.9%	-1.9%	0.8%	-5.0%
DJ Stoxx 600	2.2%	1.9%	2.2%	-4.9%

	2015	2016e	2017e	2018e
P/E	30.5x	22.1x	16.8x	14.9x
Div yield (%)	3.5%	4.1%	4.1%	4.7%


ANALYSIS

- French state-owned bank **Caisse des Dépôts (CDC)** announced yesterday evening that it was selling about **22.5 million shares** in the French environmental services company **Veolia** through an **accelerated book building process**.
- The operation represents about **4%** of the company's share capital. At yesterday's closing price (i.e. EUR20.62), the placement would represent an overall amount of c. **EUR465m**.
- Following the transaction, the Caisse des Dépôts will hold **4.62%** of Veolia's share capital and **8.36%** of the company's voting rights. CDC said it intends to remain a key shareholder in the company and will remain on the Board of Directors, for the time being.
- The company's **free-float** will now amount to c. **83.5%** (vs. 79.5% before the placement).

Shareholding structure before the placement



Shareholding structure following the placement



VALUATION

- Buy, FV @ EUR23.5**
- At the current share price, Veolia is trading at **6.0x** its 2016e EBITDA multiple.

NEXT CATALYSTS

- 3rd November 2016: Q3 2016 results

[Click here to download](#)

Pierre-Antoine Chazal, pachazal@bryangarnier.com

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.8%

NEUTRAL ratings 33.1%

SELL ratings 11%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle Prudential et de Résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11



BRYAN, GARNIER & Co

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....